Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
03. Februar 2021 21:14 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
02. Februar 2021 12:31 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced...
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
01. Februar 2021 19:32 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that...
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
28. Januar 2021 16:05 ET
|
Novavax, Inc.
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK...
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
22. Januar 2021 17:23 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
22. Januar 2021 16:49 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
15. Januar 2021 08:00 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
07. Januar 2021 18:14 ET
|
Novavax, Inc.
Advance Purchase Agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidateInitial doses expected to be delivered as early as mid-2021 GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE...
Novavax to Participate in Upcoming Conferences
06. Januar 2021 09:00 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
28. Dezember 2020 09:21 ET
|
Novavax, Inc.
PREVENT-19 will assess the efficacy, safety and immunogenicity of NVX-CoV2373 in the prevention of COVID-19Trial to enroll up to 30,000 volunteers across approximately 115 sites in the U.S. and...